Eli Lilly And Company (LLY) closed at $1443.50 on November 13, 2026, up 1.3% from the previous close, on volume of 1,750,266 shares (30-day average 2,679,766).
Data as of November 13, 2026.
13-Nov-2026
| # | Date | Strategy | Legs | Contracts |
|---|---|---|---|---|
| 1 | Nov 3, 2026 | Put Butterfly | 19-Mar-27800 : 1000[2x] : 1200 P | 3,216 |
| 2-3 | The next 2 largest trades are for Premium members. Start a 7-day free trial | |||
Ranked by contracts: multi-leg trades of 200 or more contracts on one day, through Nov 13, 2026. See the 10 largest for 30, 60 and 90 days
Lilly’s Zepbound shows promise in teen obesity trial
Seeking Alpha News (Sun, 15-Nov 6:38 PM ET)
SA Asks: What are the most attractive Big Pharma stocks right now?
Seeking Alpha News (Sun, 15-Nov 2:56 PM ET)
The Week That Was, The Week Ahead: Macro and Markets, November 15
TipRanks (Sun, 15-Nov 4:14 AM ET)
GLP-1s can save health system money if priced below $350 a month: analysis
Seeking Alpha News (Sat, 14-Nov 5:26 PM ET)
PRNewswire (Sat, 14-Nov 12:01 PM ET)
Analysts’ Top Healthcare Picks: AngioDynamics (ANGO), Zevra Therapeutics (ZVRA)
TipRanks (Fri, 13-Nov 4:30 PM ET)
Viking Therapeutics gains amid report of renewed takeover interest
Seeking Alpha News (Fri, 13-Nov 1:13 PM ET)
Eli Lilly Advances Early ALS Drug Study, but Investors Must Wait for Data
TipRanks (Fri, 13-Nov 11:32 AM ET)
Eli Lilly breaks ground on $3.5B Pennsylvania manufacturing site for obesity meds
Seeking Alpha News (Thu, 12-Nov 5:18 PM ET)
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Eli Lilly And Company trades on the NYSE stock market under the symbol LLY.
As of November 13, 2026, LLY stock price climbed to $1,443.50 with 1,750,266 million shares trading.
LLY has a beta of -0.00, meaning it tends to be less sensitive to market movements. LLY has a correlation of 0.00 to the broad based SPY ETF.
LLY has a market cap of $1.29 trillion. This is considered a Mega Cap stock.
Last quarter Eli Lilly And Company reported $24 billion in Revenue and $7.48 earnings per share. This beat revenue expectation by $2 billion and exceeded earnings estimates by $1.12.
In the last 3 years, LLY traded as high as $1,460.00 and as low as $561.65.
The top ETF exchange traded funds that LLY belongs to (by Net Assets): VTI, VOO, IVV, SPY, VUG.
LLY has outperformed the market in the last year with a price return of +42.2% while the SPY ETF gained +13.4%. LLY has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +19.9% and +2.0%, respectively, while the SPY returned -2.8% and -0.2%, respectively.
LLY support price is $1,390.19 and resistance is $1,460.91 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that LLY shares will trade within this expected range on the day.
